Good MorningEquity markets pulled back from their new highs on Thursday after a double-shot of news gave the market a dose of reality. The October read of CPI came in above expectations, belying the need for aggressive FOMC rate cuts, while jobless claims data came in at the highest level in two years. The jobless claims raise fear of a recession even while inflation remains hot. At 258,000 weekly new claims, the unemployment data shows a sharp increase in newly jobless Americans but is offset by a decline in total joblessness. The takeaway is that the data remains spotty, and the US economy is on track for a soft landing.
Next week will be challenging for equity markets. Earnings season will continue its ramp to high gear with reports from big pharma and the first of the FAANG names. Netflix is expected to report on Thursday after the market close and has a high bar to beat. More than 90% of the analysts covering Netflix have raised their estimates for the quarter, forecasting a 15% YoY gain in revenue, and whisper numbers are much higher. The question is not whether Netflix can produce value but whether competition and consumer weakness will sap strength and impact the longer-term growth outlook.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Industrials | |
Airline and transportation stocks have been under pressure from weakening consumer discretionary trends lately, especially as inflation is now threatening to spike again after the – arguably premature – interest rate cuts coming from the Federal Reserve (the Fed), being the most aggres... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Consumer Discretionary | |
While the world of e-commerce in the United States and Europe is dominated by Amazon.com Inc. (NASDAQ: AMZN) and arguably shared with Chinese giant Alibaba Group (NYSE: BABA), a new Latin American territory has been taken over by the region’s leading platform instead, with a particular inter... Read the Full Story |
|
Consumer Discretionary | |
Domino’s Pizza (NYSE: DPZ) continues to face challenges but is navigating the conditions well. The Q3 results show that the Hungry for MORE strategy continues to pay off, setting the business up for accelerating growth and leveraging bottom-line results when macroeconomic conditions improv... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Healthcare | |
Small-cap stocks faced a challenging environment for the last several years as inflation and high interest rates dampened lending opportunities. These companies—which are often in the early stages of development and lack stability—rely heavily on debt to fuel their growth.
Fortunately... Read the Full Story |
|
Consumer Discretionary | |
Analysts' sentiment is important in determining the right time to buy stock. However, the trend in sentiment and coverage is more important than the consensus rating. A Moderate Buy or Buy rating doesn’t mean as much if recent revisions include downgrades, price target revisions, and lapsed ... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Healthcare | |
The stock market’s impressive and resilient performance in 2024, with the SPDR S&P 500 ETF (NYSE: SPY) up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time highs. However, this approach can be risky as stocks stretched to the upsid... Read the Full Story |
|
Consumer Discretionary | |
On a day when the benchmark S&P 500 index hit a record high, Carnival Corporation's (NYSE: CCL) popping 7% to its highest level in more than 2 years says a lot. As one of the hardest hit industries during the COVID pandemic, cruise lines have been closely watched in recent years to see if they... Read the Full Story |
|
Technology | |
There’s a saying that stocks don’t move in one direction all the time. Palantir Technologies Inc. (NYSE: PLTR) is testing the logic behind that saying. PLTR stock is up a whopping 151% in 2024 nearly matching the 168% gain in NVIDIA Corp. (NASDAQ: NVDA).
Furthermore, the stock is up ... Read the Full Story |
|
Markets | |
Now that the stock market is going into a new trend and cycle, sparked by the recent Federal Reserve (the Fed) interest rate cuts initiating a potential money shift over the next few quarters, investors might start to prefer safer spaces and stocks to put their capital into. Among all these prefer... Read the Full Story |
|
Markets | |
It might seem strange to say a stock is still irresistible after it’s rallied 350% and just closed at a new high, but it’s hard not to with Netflix, Inc (NASDAQ: NFLX). For a company that had to watch its shares lose 80% of their value just 2 years ago, it’s been a remarkable tur... Read the Full Story |
|
Friday's Early Bird Stock Of The Day GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. | Should I Buy GSK Stock? GSK Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of GSK was last updated on Sunday, August 30, 2026 at 6:25 PM.
GSK Bull Case -
The company has set its FY 2026 guidance at an earnings per share (EPS) range of 4.900-5.000, indicating strong future profitability potential.
-
GSK plc recently increased its quarterly dividend to $0.4515, reflecting a commitment to returning value to shareholders, with an annualized dividend yield of approximately 3.6%.
-
The stock has a market capitalization of around $104.62 billion, suggesting a stable and significant presence in the pharmaceutical industry.
-
With a P/E ratio of 16.17, GSK plc may be considered reasonably valued compared to its earnings, which can be attractive for investors looking for growth at a fair price.
-
Recent institutional interest has been notable, with several large investors increasing their stakes, indicating confidence in GSK plc's future performance.
GSK Bear Case -
The P/E/G ratio of 2.98 suggests that the stock may be overvalued relative to its growth rate, which could deter value-focused investors.
-
Despite the recent dividend increase, the payout ratio stands at 55.63%, which may raise concerns about the sustainability of future dividends if earnings do not grow as expected.
-
The stock's beta of 0.35 indicates lower volatility compared to the market, which might not appeal to investors seeking high-risk, high-reward opportunities.
-
GSK plc operates in a highly competitive pharmaceutical market, which can pose risks to its market share and profitability.
-
Recent fluctuations in institutional ownership may indicate uncertainty among large investors regarding the company's long-term prospects.
| | View Today's Stock Pick |
|
